PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsSELICRELUMAB
Selicrelumab
Selicrelumab is an antibody pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
126 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Blood pressureD001794EFO_0004325————1—1
Platelet activationD015539—————1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SyndromeD013577——131——4
Diabetes mellitusD003920EFO_0000400E08-E13131—14
Type 1 diabetes mellitusD003922EFO_0001359E10131—14
Sjogren's syndromeD012859EFO_0000699M35.0—21——3
Thrombocytopenic purpura idiopathicD016553EFO_0007160D69.3——1—12
ThrombocytopeniaD013921HP_0001873D69.6111——2
Thrombocytopenic purpuraD011696————1—12
PurpuraD011693HP_0000979D69.2——1—12
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C80203———21
MelanomaD008545——149———18
Pancreatic neoplasmsD010190EFO_0003860C25123———12
CarcinomaD002277—C80.0104———12
LymphomaD008223—C85.993———11
Non-hodgkin lymphomaD008228—C85.983———10
AdenocarcinomaD000230——66———8
Non-small-cell lung carcinomaD002289——73———8
LeukemiaD007938—C9581———8
B-cell chronic lymphocytic leukemiaD015451—C91.171———7
Show 69 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
B-cell lymphomaD016393——5————5
Multiple myelomaD009101—C90.04————4
Plasma cell neoplasmsD054219——4————4
Glandular and epithelial neoplasmsD009375——4————4
Follicular lymphomaD008224—C823————3
Renal cell carcinomaD002292EFO_0000376—3————3
Neoplasm metastasisD009362EFO_0009708—2————2
Merkel cell carcinomaD015266EFO_1001471C4A2————2
GliomaD005910EFO_0000520—2————2
MyoepitheliomaD009208——2————2
Show 32 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Primary immunodeficiency diseasesD000081207——————22
Chronic kidney failureD007676EFO_0003884N18.6————11
Humoral immunityD056724——————11
Coronary diseaseD003327——————11
Acute coronary syndromeD054058EFO_0005672—————11
Coronary artery diseaseD003324—I25.1————11
Myocardial ischemiaD017202EFO_1001375I20-I25————11
InflammationD007249MP_0001845—————11
Atherosclerotic plaqueD058226HP_0031678I70————11
Septic shockD012772—A48.3————11
Show 13 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSelicrelumab
INNselicrelumab
Description
CP-870893 (mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL2109477
ChEBI ID—
PubChem CID—
DrugBank—
UNII ID0O39RGI33V (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 75,063 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
79 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use